Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study

• Atsuo Takashima,
• Narikazu Boku,
• Taroh Satoh,
• Shigenori Kadowaki,
• Kei Muro,
• Shigehisa Kitano,
• Kensei Yamaguchi,
• Keisho Chin,
• Marianna Zavodovskaya,
• Dung Thai,
• Akie Kimura Yoshikawa,
• Takashi Ichimura,
• Daisuke Sakai,
• Toshihiro Kudo,
• Seiichiro Mitani,
• JieJane Liu

Affiliations

Atsuo Takashima

Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

Narikazu Boku

Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

Taroh Satoh

Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan

Shigenori Kadowaki

Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

Kei Muro

Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

Shigehisa Kitano

Department of Experimental Therapeutics, National Cancer Center Hospital, Goyang, Republic of Korea

Kensei Yamaguchi

Department of Gastroenterology, Japanese Foundation for Cancer Research, Tokyo, Japan

Keisho Chin

Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Marianna Zavodovskaya

Gilead Sciences Inc, Foster City, California, USA

Dung Thai

Gilead Sciences Inc, Foster City, California, USA

Akie Kimura Yoshikawa

Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan

Takashi Ichimura

Department of Gastrointestinal Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Daisuke Sakai

Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan

Toshihiro Kudo

Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan

Seiichiro Mitani

Department of Medical Oncology, Kindai University, Higashiosaka, Japan

JieJane Liu

Gilead Sciences Inc, Foster City, California, USA